- Details
- Howard Soule joins Charles Ryan to discuss the Coffey-Holden Prostate Cancer Academy, an annual scientific event hosted by the Prostate Cancer Foundation that mixes young and senior investigators to discuss diverse topics faced by men with advanced prostate cancer. The event aims to give young investigators a podium and an opportunity to interact with selected senior investigators. About 80% of th...
|
- Details
- Charles Ryan hosts a discussion about the annual Coffey-Holden meeting, a think tank devoted to prostate cancer, with Howard Soule, Ken Pienta, and Andrea Miyahira. Originating in the 1980s, the meeting promotes collaboration, mentorship, and innovation in prostate cancer research. Recent topics include health disparities, particularly among people of African ancestry, the responsible use of real-...
|
- Details
- Alicia Morgans speaks with Jeff Tosoian, PCF Young Investigator Award recipient, about his groundbreaking work on developing minimally invasive tactics to understand aggressive cancers. Dr. Tosoian, along with his multidisciplinary team, is keenly focused on creating a urine-based approach that could potentially revolutionize the process of diagnosing high-grade prostate cancer. The team has ident...
|
- Details
- In this conversation Michael Milken, Isla Garraway, and Kneeland Youngblood join Charles Ryan in a conversation on disparities and trends in the incidence and mortality of prostate cancer in the United States. To guide their conversation and to understand why Black men have a higher incidence, a higher death rate, and that relation to genetics and the microbiome, they highlight a December 2022 Eur...
|
- Details
- In this discussion between Alicia Morgans and Alexander Wyatt, the two delve into the complexities of using circulating tumor DNA (ctDNA) in the treatment of prostate cancer. Dr. Wyatt explains the advantages of ctDNA in the metastatic setting, highlighting its minimally invasive nature and ease of collection compared to tissue biopsy. He emphasizes the importance of timing and patient selection i...
|
- Details
- Alicia Morgans interviews Nick Zorko, who shares his excitement about his team's work on natural killer (NK) cell therapies, specifically focusing on engineered NK cells to target the tumor marker B7-H3. Unlike most T-cell based approaches, this project aims at treating prostate cancer with modified NK cells. Their modifications include adding a chimeric antigen receptor specific for B7-H3 and par...
|
- Details
- Andrea Alimonti discusses the challenges and advancements in the understanding and treatment of castration-resistant prostate cancer (CRPC). Dr. Alimonti highlights his team's efforts to comprehend the mechanisms of CRPC initiation and progression and explores potential therapies that could reverse or treat CRPC using anti-tumor immune responses. He emphasizes his team's contributions to the field...
|
- Details
- Charles Ryan and Isra Elhussin engage in an enlightening conversation about the disparities in cancer genomic profiling between African and European ancestries. Dr. Elhussin's pioneering research investigates how genetic ancestry and specific gene mutations, notably SPOP mutations more prevalent in those of African ancestry, influence prostate cancer subtypes and treatment responses. Her study hig...
|
- Details
- Researcher and associate professor Isla Garraway joins Alicia Morgans in a discussion on ongoing prostate cancer research and current initiatives in the Veteran's Affairs (VA) Care Program. With support from the Prostate Cancer Foundation (PCF) Garraway is part of a team of physician-scientists working to ensure our veterans have access to the same precision oncology medications and clinical trial...
|
- Details
- Matthew Rettig and Isla Garraway discuss the progress and aspirations of the Veterans Administration (VA) prostate cancer program, established through a Memorandum of Understanding with the Prostate Cancer Foundation. The program has expanded from six to 13 Centers of Excellence, with the VA committing $50 million to this initiative. Dr. Rettig emphasizes the program's focus on precision oncology,...
|
